| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794932 | Ophthalmology Retina | 2017 | 8 Pages |
Abstract
The 12-week results of this trial disclosed that both 1.25 mg and 2.5 mg doses of IVZ and IVB demonstrated BCVA improvement over baseline in the treatment of center-involved DME. However, a stronger effect of IVZ compared with IVB in terms of both visual acuity improvement and macular thickness reduction was detected in the eyes with initial BCVA <20/50. Longer-term efficacy and safety data will be needed to understand the role for this drug in practice.
Keywords
IVBDMEERGCMTBCVAlogMARIntravitreal bevacizumabDiabetic macular edemaelectroretinographyOctbest-corrected visual acuityOptical coherence tomographyVisual acuityCentral macular thicknessVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)logarithm of the minimum angle of resolution
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ahmadreza MD, Mohammad Hossein MD, Alireza MD, Mohsen MD, Siamak MD, Mohammad Hossein MD, Ramin MD, Gholam A. MD, Mehdi PhD, Masoud MD,